Ratings Hamilton Thorne Ltd. Toronto S.E.

Equities

HTL

CA4078911001

Market Closed - Toronto S.E. Other stock markets 01:29:59 04/05/2024 am IST			5-day change	1st Jan Change
1.4 ^CAD	+0.72%		+2.94%	+5.26%

27/03	Hamilton Thorne's Q4 Profit Falls, Sales Rise; Provides 2024 Outlook	MT
27/03	Hamilton Thorne Brief: 2024 guidance is for a sales range between US$78 and $82 million representing 10-15% organic growth; Q1 guidance is for a sales range of $19.0 to $19.4 million	MT

Summary

Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

Over the past year, analysts have regularly revised upwards their sales forecast for the company.
Sales forecast by analysts have been recently revised upwards.
For several months, analysts have been revising their EPS estimates roughly upwards.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Considering the small differences between the analysts' various estimates, the group's business visibility is good.

Weaknesses

The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 46.67 times its estimated earnings per share for the ongoing year.

Ratings chart - Surperformance

Sector: Advanced Medical Equipment & Technology

	1st Jan change	Capi.	ESG Refinitiv
HAMILTON THORNE LTD.	+5.26%	156M	-
THERMO FISHER SCIENTIFIC	+7.84%	218B	B
DANAHER CORPORATION	+7.35%	184B	B-
INTUITIVE SURGICAL, INC.	+13.04%	135B	B-
BOSTON SCIENTIFIC CORPORATION	+26.03%	107B	A-
SIEMENS HEALTHINEERS AG	-1.33%	62.38B	A-
EDWARDS LIFESCIENCES CORPORATION	+11.80%	51.37B	B+
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+4.81%	50.9B	B+
AGILENT TECHNOLOGIES, INC.	+0.30%	40.87B	A
GE HEALTHCARE TECHNOLOGIES INC.	+2.78%	36.28B	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes